• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.

作者信息

Begna Kebede H, Gangat Naseema, Al-Kali Aref, Litzow Mark R, Hogan William J, Patnaik Mrinal M, Pardanani Animesh, Hook C Christopher, Wolanskyj Alexandra P, Elliott Michelle A, Hanson Curtis A, Ketterling Rhett P, Tefferi Ayalew

机构信息

Divisions of Hematology, Mayo Clinic, Rochester, Minnesota.

Divisions of Hematopathology, Mayo Clinic, Rochester, Minnesota.

出版信息

Am J Hematol. 2021 Apr 1;96(4):E108-E111. doi: 10.1002/ajh.26112.

DOI:10.1002/ajh.26112
PMID:33527451
Abstract
摘要

相似文献

1
Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.70岁以上急性髓系白血病：强化化疗与HMA±维奈克拉化疗治疗后生存情况的回顾性比较
Am J Hematol. 2021 Apr 1;96(4):E108-E111. doi: 10.1002/ajh.26112.
2
Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.反应性血小板增多症与接受维奈克拉和低甲基化药物治疗的急性髓系白血病（AML）患者的反应相关。
Am J Hematol. 2021 May 1;96(5):E140-E143. doi: 10.1002/ajh.26117. Epub 2021 Feb 18.
3
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).接受去甲基化药物联合维奈克拉（HMA-Ven）或脂质体柔红霉素-阿糖胞苷（CPX-351）治疗的继发性急性髓系白血病的治疗结果
Am J Hematol. 2021 Jun 1;96(6):E196-E200. doi: 10.1002/ajh.26157. Epub 2021 Apr 8.
4
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.白血病遗传学与复发/难治性急性髓系白血病对维奈托克和去甲基化药物反应的关联
Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10.
5
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.地西他滨和维奈克拉治疗异柠檬酸脱氢酶1/2突变的急性髓系白血病
Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19.
6
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Venetoclax 联合治疗复发/难治性急性髓系白血病及相关髓系恶性肿瘤的临床经验。
Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23.
7
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.优化新型老年急性髓系白血病患者联合低强度治疗方案中的维奈托克剂量：暴露反应分析。
Hematol Oncol. 2019 Oct;37(4):464-473. doi: 10.1002/hon.2646. Epub 2019 Aug 2.
8
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.维奈托克联合地西他滨与强化化疗治疗急性髓系白血病的疗效比较：基于治疗相关死亡率风险的倾向评分匹配分析。
Am J Hematol. 2021 Mar 1;96(3):282-291. doi: 10.1002/ajh.26061. Epub 2020 Dec 24.
9
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.维奈托克联合低甲基化药物治疗低危急性髓系白血病的疗效
Am J Hematol. 2021 Mar 1;96(3):E59-E63. doi: 10.1002/ajh.26057. Epub 2020 Dec 8.
10
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.维奈托克联合 LDAC 方案用于不适合强化化疗的新诊断 AML：一项 3 期随机安慰剂对照试验。
Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856.

引用本文的文献

1
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).比较维奈托克联合低甲基化药物与低甲基化药物为基础的治疗方案用于初治 TP53 突变急性髓系白血病：来自髓系恶性肿瘤和肿瘤性疾病联盟（COMMAND）的结果。
Blood Cancer J. 2024 Feb 20;14(1):32. doi: 10.1038/s41408-024-01000-2.
2
Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies.维奈托克联合低甲基化药物治疗新诊断的急性髓系白血病：来自真实世界研究生存数据的系统评价和荟萃分析
Cancers (Basel). 2023 Sep 18;15(18):4618. doi: 10.3390/cancers15184618.
3
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.年龄 70 岁或以上、适合强化化疗的 AML 患者的评分系统：一项基于 DATAML、SAL 和 PETHEMA 登记处的大型欧洲数据集的研究。
Blood Cancer J. 2022 Jul 11;12(7):107. doi: 10.1038/s41408-022-00700-x.
4
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.维奈托克联合阿扎胞苷与诱导化疗治疗初诊急性髓系白血病患者的比较。
Blood Adv. 2021 Dec 28;5(24):5565-5573. doi: 10.1182/bloodadvances.2021005538.
5
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.新型低强度化疗方案（克拉屈滨或 cladribine 联合小剂量阿糖胞苷，交替应用地西他滨）治疗初诊老年急性髓系白血病的长期疗效。
Am J Hematol. 2021 Aug 1;96(8):914-924. doi: 10.1002/ajh.26206. Epub 2021 May 26.
6
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.伴有血液原始细胞增多的骨髓增生异常/骨髓增殖性肿瘤中维奈克拉联合阿扎胞苷或地西他滨：一项多中心 32 例连续病例系列研究。
Am J Hematol. 2021 Jul 1;96(7):781-789. doi: 10.1002/ajh.26186. Epub 2021 May 6.